Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial

Published:2016-08 Issue:8 Volume:17 Page:1114-1126
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

de Boer Stephanie M,Powell Melanie E,Mileshkin Linda,Katsaros Dionyssios,Bessette Paul,Haie-Meder Christine,Ottevanger Petronella B,Ledermann Jonathan A,Khaw Pearly,Colombo Alessandro,Fyles Anthony,Baron Marie-Helene,Kitchener Henry C,Nijman Hans W,Kruitwagen Roy F,Nout Remi A,Verhoeven-Adema Karen W,Smit Vincent T,Putter Hein,Creutzberg Carien L

Funder

Dutch Cancer Society, Netherlands

National Health and Medical Research Council

Italian Medicines Agency

Canadian Cancer Society Research Institute

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up;Colombo;Ann Oncol,2016

2. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis;Blake;Lancet,2009

3. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma;Creutzberg;Lancet,2000

4. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study;Keys;Gynecol Oncol,2004

5. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial;Nout;Lancet,2010

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Review of the Literature on Multiple Co-occurring Symptoms in Patients Receiving Treatment for Gynecologic Cancers;Seminars in Oncology Nursing;2024-01

2. Adjuvant carboplatin and paclitaxel with “sandwich” method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution;Journal of Gynecologic Oncology;2024

3. Assessing health-related quality of life among cancer survivors during systemic and radiation therapy in Bangladesh: a cancer-specific exploration;BMC Cancer;2023-12-07

4. Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022) – Part 2 with Recommendations on the Therapy of Precancerous Lesions and Early-stage Endometrial Cancer, Surgical Therapy, Radiotherapy and Drug-based Therapy, Follow-up Care, Recurrence and Metastases, Psycho-oncological Care, Palliative Care, Patient Education, and Rehabilitative and Physiotherapeutic Care;Geburtshilfe und Frauenheilkunde;2023-08

5. Quality of life of older gynecologic oncology patients at the initiation of chemotherapy;Nursing Open;2023-06-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3